Prediabetes & diabetes prevention

Higher daily glucose variability is associated with greater aortic stiffness irrespective of average glucose levels, indicate findings from The Maastricht Study.

The risk for subclinical atherosclerosis among people at low risk for cardiovascular death increases with increasing glycated hemoglobin levels and is raised even at levels below the prediabetes threshold, research shows.

The risk for adverse cardiorenal events begins to increase well below the glycemic level associated with type 2 diabetes, with the largest proportion of events occurring in people with prediabetic levels, shows a UK Biobank analysis.

Children with familial type 1 diabetes have different characteristics to those with sporadic diabetes at presentation, but longer-term outcomes are similar, say researchers.

A random blood glucose test in people without diabetes may provide a good indication of who has an increased risk for developing cardiovascular disease over the subsequent decade, a study suggests.

Phase 2 study results suggest that add-on treatment with an anti-IL-21 antibody plus liraglutide could preserve endogenous insulin secretion in people with recent-onset type 1 diabetes.

Prolonged follow-up of high-risk people treated with teplizumab to prevent progression to type 1 diabetes shows a lasting beneficial effect on beta-cell function, say researchers.

The incidence of diabetes in high- and middle-income countries may at last be stabilizing, or even in decline, say researchers.

Delaying progression from impaired glucose tolerance to type 2 diabetes reduces the risk for micro- and macrovascular complications, shows 24 years of follow-up of the Da Qing trial.

Adults who develop prediabetes when older than 70 years are more likely to regress to normoglycemia or die of other causes than to progress to type 2 diabetes, research shows.

Use of the SGLT2 inhibitor dapagliflozin is associated with a reduced risk for new-onset type 2 diabetes in high-risk individuals with heart failure and reduced ejection fraction, suggests an exploratory analysis of data from the DAPA-HF trial.

A randomized trial indicates that testosterone treatment among men with prediabetes or newly diagnosed type 2 diabetes significantly reduces the risk for them having type 2 diabetes 2 years later.

The SGLT2 inhibitor empagliflozin may reverse adverse left ventricular remodeling in people who have heart failure with reduced ejection fraction and type 2 diabetes or prediabetes, shows a randomized trial.

Lifestyle intervention significantly reduces the risk for type 2 diabetes in people who have prediabetes based on fasting plasma glucose or glycated hemoglobin measurements, show findings from a randomized trial.